SCHEMBL2706418

SCHEMBL2706418

O=C(O)C1CCCN1S(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.64
HCRTR2 O43614 1/20 0.64
CCR4 P51679 1/20 0.60
LMNA P02545 1/20 0.59
KDM4E B2RXH2 1/20 0.58
TSHR P16473 1/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
BRD4 O60885 1/20 0.54
HTT P42858 1/20 0.54
HTR7 P34969 5/20 0.54
HTR1D P28221 3/20 0.54
HTR2B P41595 3/20 0.54
HTR1A P08908 2/20 0.54
DRD2 P14416 2/20 0.54
DRD3 P35462 2/20 0.54
HTR1B P28222 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
ADRA1B P35368 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705837 1.00 HCRTR1 (0.64) HCRTR1HCRTR2CCR4LMNAKDM4E
SCHEMBL6920928 0.84 HCRTR1 (0.58) HCRTR1HCRTR2CCR4LMNAHTT
SCHEMBL8842866 0.83 KDM4E (0.57) HCRTR1HCRTR2CCR4KDM4ETSHR
SCHEMBL5743967 0.81 KMT2A (0.60) HCRTR1HCRTR2CCR4KDM4ETSHR
SCHEMBL5743956 0.81 KMT2A (0.60) HCRTR1HCRTR2CCR4KDM4ETSHR
SCHEMBL31363195 0.81 KMT2A (0.60) HCRTR1HCRTR2CCR4KDM4ETSHR
SCHEMBL19976337 0.81 KDM4E (0.53) HCRTR1HCRTR2CCR4LMNAKDM4E
SCHEMBL1398899 0.81 HCRTR1 (0.55) HCRTR1HCRTR2CCR4LMNATSHR
SCHEMBL3727147 0.81 MMP8 (0.58) LMNAKDM4ETSHRCASP1CASP7
SCHEMBL5062486 0.81 HTT (0.53) LMNAKDM4ETSHRCASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 US claimed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 US claimed
US-9211279-B2 Proline sulfonamide derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2015-12-15 US disclosed
US-20150246021-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-03 US disclosed
CN-103079563-B Proline sulfonamide derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD 2015-07-08 CN disclosed
US-9000029-B2 Proline sulfonamide derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2015-04-07 US disclosed
US-20150057328-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS IDORSIA PHARMACEUTICALS LTD (CH) 2015-02-26 US disclosed
US-8895606-B2 Proline sulfonamide derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-11-25 US disclosed
EP-2608787-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2013-07-03 EP disclosed
US-20130150424-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2013-06-13 US disclosed
CN-103079563-A Proline sulfonamide derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD 2013-05-01 CN disclosed
WO-2012025877-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2012-03-01 WO disclosed
EP-1244621-B1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS HOFFMANN LA ROCHE (CH) 2006-09-13 EP disclosed
CN-1240681-C Nitrile derivatives as cathepsin K inhibitors HOFFMANN LA ROCHE (CH) 2006-02-08 CN disclosed
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 US disclosed
EP-1244621-A1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-10-02 EP disclosed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 US disclosed
WO-2001047886-A1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057328-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 HCRTR1 2/4885HCRTR2 1/4885CCR4 1598/4885
US-20130150424-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 HCRTR1 2/4885HCRTR2 1/4885CCR4 1598/4885
US-20150246021-A1 PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 HCRTR1 2/4885HCRTR2 1/4885CCR4 1573/4885
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K CTSK, CTSH, CTSS HCRTR1 2039/4885HCRTR2 2362/4885CCR4 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.